If you have been reading about GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The first two bases in the codon create the coding specificity, for they form strong Watson–Crick base pairs and bond strongly to the anticodon of the tRNA. When reading 5' to 3' the first nucleotide in the anticodon (which is on the tRNA and pairs with the last nucleotide of the codon on the mRNA) determines how many nucleotides the tRNA actually distinguishes. If the first nucleotide in the anticodon is a C or an A, pairing is specific and acknowledges original Watson–Crick pairing, that is: only one specific codon can be paired to that tRNA. If the first nucleotide is U or G, the pairing is less specific and in fact two bases can be interchangeably recognized by the tRNA. Inosine displays the true qualities of wobble, in that if that is the first nucleotide in the anticodon, any of three bases in the original codon can be matched with the tRNA. Due to the specificity inherent in the first two nucleotides of the codon, if one amino acid is coded for by multiple anticodons and those anticodons differ in either the second or third position (first or second position in the codon) then a different tRNA is required for that anticodon. The minimum requirement to satisfy all possible codons (61 excluding three stop codons) is 32 tRNAs. That is 31 tRNAs for the amino acids and one initiation codon.
== Uses == In Hawaii, it is commonly used in long-lasting leis since it retains its shape and color after drying. In Nepal, the flower is known commonly as makhamali ful and is used to make a garland during Bhai Tika, last day of Tihar festival. The garland is put around the brother's neck by their sister for protection. The slow withering character of the flower symbolizes a long life for the brother. The flower was included in the gift sent to Britain by Jung Bahadur Rana in 1855. This flower is known as Rakta Mallika in Sanskrit. This plant is common in landscape design and cutting gardens for its vivid colors and color retention. The edible plant G. globosa has been used in herbal medicine. The flowers of G. globosa are rich in betacyanins which have a wide range of applications as additives and supplements in the food industry, cosmetics, and livestock feed. Stable between pH 3 and 7, the betacyanins in globe amaranth are well suited to be used as natural food dye and have a red-violet color.
Richmond – This rivalry stems out of the 1942 Grand Final which Essendon won. In 1974, a half-time brawl took place involving trainers, officials and players at Windy Hill and has become infamous as one of the biggest ever. The teams didn't meet in the finals between 1944 and 1995, but there have been many close margins in home and away season matches as a result of each team's "never say die" attitude and ability to come back from significant margins in the dying stages of matches. Having met in the AFL's Rivalry Round in (2006 and 2009) and meeting in the Dreamtime at the 'G match since 2005, the rivalry and passion between the clubs and supporters has re-ignited. In recent years the rivalry has been promoted as the "Clash of the Sash". Hawthorn – The two sides had a number of physical encounters in the mid-1980s when they were the top two sides of the competition. The rivalry was exacerbated when Dermott Brereton ran through Essendon's three-quarter time huddle during a match in 1988 and again by an all in brawl during a match in 2004 allegedly instigated by Brereton (now known as the Line in the Sand Match after the direction allegedly given by Brereton for the Hawthorn players to make a physical stand). This was reminiscent of the 1980s when battles with Hawthorn were often hard and uncompromising affairs. During Round 22 of the 2009 season, Essendon and Hawthorn played for the last finals spot up for grabs. The teams played out an extremely physical game and despite being 22 points down at half time Essendon went on to win by 17 points.
In ancient times, one highly abrasive depilatory paste consisted of an admixture of slaked lime, water, wood-ash and yellow orpiment (arsenic trisulfide); In rural India and Iran, where this mixture is called vajibt, it is still commonly used to remove pubic hair. In other cultures, oil extracted from unripe olives (which had not reached one-third of their natural stage of ripeness) was used to remove body hair. During the medieval period, Catholic women were expected to let their hair grow long as a display of femininity, whilst keeping the hair concealed by wearing a wimple headdress in public places. The face was the only area where hair growth was considered unsightly; 14th-century ladies would also pick off hair from their foreheads to recede the hairline and give their face a more oval form. From the mid-16th century, it is said when Queen Elizabeth I came to power, she made eyebrow removal fashionable. By the 18th century, body hair removal was still considered a non-necessity by European and American women. But in 1760, when the first safety straight razor appeared for men to safely shave their beard and not inadvertently cut themselves, some women allegedly used this safety razor too. It was invented in Paris by the French master cutler Jean-Jacques Perret, author of La pogonotomie, ou L'art d'apprendre à se raser soi-même (Pogonotomy, or The Art of Learning to Shave). It was not until the late 19th century that women in Europe and America started to make hair removal a component of their personal care regime.
== Society and culture == Vaginal mesh kits were introduced to the U.S. market in 2004 through the U.S. Food and Drug Administration (FDA) pathway that did not require companies to demonstrate both safety and efficacy of the product if they were able to demonstrate that their product was similar to previous products already in the market. However, there was concern over reports of increased rates of postoperative complications over the next several years. That, in addition to the lack of available data that transvaginal mesh products were superior to other forms of surgical intervention and the expedited process which the vaginal mesh kits were introduced to the market, the FDA released a Safety Communication in 2011 that described serious complications associated with transvaginal mesh as "not rare". In 2019, the FDA ordered manufacturers to halt sales of transvaginal mesh intended for repair of pelvic organ prolapse. This does not include surgical mesh used during sacrocolpopexy, sacrohysteropexy, or transurethral sling procedures. Since 2008, a number of class action lawsuits have been filed and settled against several manufacturers of transvaginal mesh after people reported complications following surgery.
Sources: en.wikipedia.org
== See also == Protein serine/threonine phosphatase, enzyme for reverse process. Pseudokinase, a protein without enzyme activity (pseudoenzyme). It can be related to proteins of this class. ATM serine/threonine kinase, responsible for the disorder ataxia–telangiectasia.
A central campaign theme for Trump's second presidential bid was "retribution". Trump framed the 2024 election as "the final battle", and openly promised to leverage the power of the presidency for political reprisals. Trump heavily ran on immigration as a central campaign focus. Trump's campaign focused on dark and apocalyptic rhetoric about the state of the country and predicting doom if he did not win. The Associated Press stated that "Trump's rallies take on the symbols, rhetoric and agenda of Christian nationalism." During his 2024 presidential campaign, Trump made numerous false and misleading statements. Trump has been described as using the "big lie" and firehose of falsehood propaganda techniques.
The PLA began as an all-volunteer force. In 1955, as part of an effort to modernize the PLA, the first Military Service Law created a system of compulsory military service. Since the late 1970s, the PLA has been a hybrid force that combines conscripts and volunteers. Conscripts who fulfilled their service obligation can stay in the military as volunteer soldiers for a total of 16 years. De jure, military service with the PLA is obligatory for all Chinese citizens. However, mandatory military service has not been enacted in China since 1949. Due to the effect of the one-child policy, over 70 percent of the PLA and 80 percent of its combat troops come from one-child households, according to Liu Mingfu of the National Defense University.
Hydra ( HY-drə) is a genus of small freshwater hydrozoans in the phylum Cnidaria. They are solitary, carnivorous jellyfish-like animals, native to the temperate and tropical regions. The genus was named by Linnaeus in 1758 after the Hydra, the mythical many-headed beast that was defeated by Heracles, as when the animal has a part severed, it will regenerate much like the mythical Hydra's heads. Biologists are especially interested in Hydra because of their regenerative ability; they do not appear to die of old age, or to age at all.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.